K.G. Jebsen Coeliac Disease Research Centre
The primary objective of our centre is to translate recent huge advances in the basic understanding of the pathogenesis of coeliac disease to the clinic – to improve disease diagnostics, to implement novel treatments and to identify new therapeutic targets for this common disease.
The secondary objective is to become a clinical research site at the international forefront which will provide optimal patient care and which will be a unique training site for basic scientists and clinicians.
Transglutaminase 2 inhibitor shows great promise in clinical trial
Sep. 29, 2021 10:44 AM
Transglutaminase 2 (TG2) activity is essential to induce a pathogenic immune response towards gluten in coeliac disease. In a Phase 2 clinical trial, a daily dose of an irreversible TG2-inhibitor prevented gluten-induced mucosal destruction in coeliac patients that consumed gluten daily for 6 weeks. These findings represents a milestone in the search for treatment options for patients with coeliac disease.
Is regular gluten free diet sufficient to curb all anti-gluten immunity?
Feb. 17, 2021 10:52 PM
Proteomics analysis of intestinal tissue biopsies finds that some patients with celiac disease considered to be well treated by regular gluten free diet have ongoing low-level inflammation in the intestine suggestive of ongoing low-level anti-gluten immunity. These patients developed strong intestinal response following 14 -day gluten challenge. We are now investigating whether some patients may still have activated gluten-specific T-cells despite long-term gluten free diet.
- Insights from tissue "omics" analysis on intestinal remodeling in celiac disease Oct. 11, 2021 11:00 AM
- Differential expression profile of gluten-specific T cells identified by single-cell RNA-seq Oct. 7, 2021 11:00 AM
- Single-cell approaches to dissect adaptive immune responses involved in autoimmunity: the case of celiac disease Sep. 17, 2021 11:00 AM